Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boston's Clik Anchor spinal lead fixation device approved in the US

This article was originally published in Clinica

Executive Summary

The Clik Anchor, a device developed by Boston Scientific to aid placement of its Precision Plus spinal cord stimulator, has gained US premarket approval (PMA). The Clik Anchor uses a locking system to fix the leads – the wires through which painkilling impulses pass – more quickly and consistently. It locks into place on the lead with a turn of an Allen key and provides tactile and audible confirmation that the lead is secured. The firm will launch the Clik Anchor immediately. The Precision Plus is indicated for the management of chronic intractable pain of the trunk and/or limbs. The leads themselves were approved in the US last year (www.clinica.co.uk, 2 August 2010)

You may also be interested in...



Falling Sales Force New Priorities At Roche

The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.

BMS Has A Strong Pipeline, But Access Challenges Remain

Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.

Normality Reasserts Itself For Biotech IPOs

The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT096988

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel